ALE.C04

DRUG2 trials

Sponsors

Alentis Therapeutics AG

Conditions

Head and Neck CancerHead and Neck Squamous Cell CarcinomaRecurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

Phase 1

Study of ALE.C04 in Patients With Head and Neck Cancer

TerminatedNCT06054477

Alentis Therapeutics AGHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma

Start: 2023-10-30End: 2025-02-12Updated: 2025-02-17

A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

CompletedCTIS2023-505145-93-00

Alentis Therapeutics AGRecurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

Start: 2024-03-21End: 2025-02-11Target: 104Updated: 2025-02-11

Related Papers

Abstract 7338: Evaluation of a novel target Claudin1 in preclinical models of nasopharyngeal carcinoma

Cancer Research2025-04-21